Molbio Diagnostics IPO: ₹930 Cr Issue Opens Aug 10
A technician operates a Molbio Diagnostics Truenat rapid disease testing platform.
Key Highlights
Molbio Diagnostics IPO launches Aug 10-12, priced at ₹768-807. The ₹930.7 Cr issue includes a ₹200 Cr fresh component for R&D and expansion.
Molbio Diagnostics, the Goa-based firm behind the Truenat rapid disease testing platform, will launch its (IPO) on August 10. The ₹930.7 crore offering includes a fresh issue of ₹200 crore and an offer for sale by existing shareholders.
- Total IPO Size: ₹930.7 crore
- Component: ₹200 crore
- Share : ₹768-807 per share
- Period: August 10-12
- Scheduled Listing: August 17
The company’s rapid diagnosis technology, specifically for conditions like TB and COVID-19, has secured endorsement from the World Health Organization (WHO). This highlights the platform’s global recognition.
Future Investments
- Establishing a new research and development facility.
- Developing a Centre of Excellence via its wholly-owned subsidiary, Bigtec.
- Upgrading existing office infrastructure.
- Procuring plant, machinery, and equipment for manufacturing units in Goa and Visakhapatnam.
Backed by investors such as Temasek and Motilal Oswal, Molbio Diagnostics projects a (CAGR) of 31.5% in revenue between fiscal years 2024 and 2026. This financial outlook underlines its growth trajectory.
The IPO subscription window closes on August 12, with shares expected to list on August 17.